Drug Trial Radar · NCT06929663
A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Jul 2, 2025
Primary completion
Jun 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection, administered as monotherapy and in combination with AK104 or AK112 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
AK146D1 for injectionDrug
AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
AK112 InjectionDrug
AK112 is an anti-PD-1/VEGF-A bispecific antibody.
AK104 injectionDrug
AK104 is a recombinant bispecific human monoclonal antibody targeting both anti-programmed cell death 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4(CTLA-4) .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: During the first 3 weeks of treatment.
- Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research
Sydney, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.